Testing effectiveness (Phase 2)Study completedNCT05941481
What this trial is testing
Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ
Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Jiangsu Cancer Institute & Hospital 21